MedDataX Logo

Telmisartan/Amlodipine (80/10) vs. Telmisartan/Amlodipine (40/10) vs. amlodipine10 in Resistant Hypertension

NCT ID: NCT00553267

Last Updated: 2014-02-13

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

947 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this trial is to demonstrate that the fixed dose combination of telmisartan 40mg + amlodipine 10mg (T40/A10) or the fixed dose combination of telmisartan 80mg + amlodipine 10mg (T80/A10) is superior in reducing blood pressure at eight weeks compared with amlodipine 10mg monotherapy (A10) in patients who fail to respond to six weeks treatment with A10.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension

NCT00558428

Hypertension
COMPLETED PHASE3

26-week Open Study of telmisartan40mg+amlodipine10mg or telmisartan80mg+amlodipine10 mg in Hypertension

NCT00624052

Hypertension
COMPLETED PHASE3

Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension

NCT00860262

Hypertension
COMPLETED PHASE3

An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy

NCT01103960

Hypertension
COMPLETED PHASE3

Open Label Study Telmisartan and Amlodipine in Hypertension

NCT00614380

Hypertension
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fixed dose combination of telmisartan+amlodipine

Intervention Type DRUG

amlodipine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosis of essential hypertension and blood pressure not adequately controlled before informed consent (inadequate control defined as seated diastolic blood pressure (DBP) \>= 95 mmHg if on existing antihypertensive treatment or seated DBP \>= 100 mmHg if treatment-naïve).
* failure to respond to six weeks treatment with amlodipine 10mg. (Failure to respond defined as seated DBP \>= 90 mmHg.)
* able to stop any current antihypertensive therapy without unacceptable risk to the patient.
* willing and able to provide written informed consent.

Exclusion Criteria

* pregnancy, breast-feeding, unwilling to use effective contraception (if female of child-bearing potential).
* known or suspected secondary hypertension.
* mean seated systolic blood pressure (SBP) \>=200 mmHg and/or mean seated DBP \>= 120 mmHg during run-in treatment or mean seated SBP \>= 180 mmHg and/or mean seated DBP \>= 120 mmHg at the randomisation visit or at any time during randomised treatment.
* any clinically significant hepatic impairment or severe renal impairment bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post post-renal transplant.
* clinically relevant hyperkalaemia.
* uncorrected volume or sodium depletion.
* primary aldosteronism.
* hereditary fructose or lactose intolerance.
* symptomatic congestive heart failure.
* patients who have previously experienced symptoms characteristic of angioedema during treatment with ACE inhibitors or ARBs.
* history of drug or alcohol dependency within the six months prior to signing consent.
* concurrent participation in another clinical trial or any investigational therapy within thirty days prior to signing consent.
* hypertrophic obstructive cardiomyopathy, hemodynamically relevant stenosis of the aortic or mitral valve.
* known allergic hypersensitivity to any component of the formulations under investigation. (Includes known hypersensitivity to telmisartan or other ARBs or amlodipine or other dihydropyridine CCBs.)
* non-compliance with study medication (defined as less than 80% or more than 120%) during the open-label run-in treatment period.
* current treatment with any antihypertensive agents, whether or not prescribed for this indication, that cannot be safely stopped (investigator¿s decision) by the start of the run-in period.
* chronic administration of any medication known to affect blood pressure, other than the trial medication.
* any other clinical condition which, in the opinion of the investigator, would not allow safe completion of the protocol and safe administration of telmisartan and amlodipine.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Boehringer Ingelheim

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Boehringer Ingelheim

Role: STUDY_CHAIR

Boehringer Ingelheim

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

1235.6.61003 Boehringer Ingelheim Investigational Site

Gosford, New South Wales, Australia

Site Status

1235.6.61004 Boehringer Ingelheim Investigational Site

Liverpool, New South Wales, Australia

Site Status

1235.6.61002 Boehringer Ingelheim Investigational Site

Kippa-Ring, Queensland, Australia

Site Status

1235.6.61001 Boehringer Ingelheim Investigational Site

Milton, Queensland, Australia

Site Status

1235.6.61005 Boehringer Ingelheim Investigational Site

Elizabeth Vale, South Australia, Australia

Site Status

1235.6.43007 Boehringer Ingelheim Investigational Site

Eggenburg, , Austria

Site Status

1235.6.43006 Boehringer Ingelheim Investigational Site

Hainburg A.d. Donau, , Austria

Site Status

1235.6.43005 Boehringer Ingelheim Investigational Site

Hartberg, , Austria

Site Status

1235.6.43001 Boehringer Ingelheim Investigational Site

Vienna, , Austria

Site Status

1235.6.43002 Boehringer Ingelheim Investigational Site

Vienna, , Austria

Site Status

1235.6.43003 Boehringer Ingelheim Investigational Site

Vienna, , Austria

Site Status

1235.6.35912 Boehringer Ingelheim Investigational Site

Burgas, , Bulgaria

Site Status

1235.6.35902 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

Site Status

1235.6.35903 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

Site Status

1235.6.35904 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

Site Status

1235.6.35905 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

Site Status

1235.6.35906 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

Site Status

1235.6.35907 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

Site Status

1235.6.35910 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

Site Status

1235.6.35911 Boehringer Ingelheim Investigational Site

Sofia, , Bulgaria

Site Status

1235.6.35901 Boehringer Ingelheim Investigational Site

Varna, , Bulgaria

Site Status

1235.6.42002 Boehringer Ingelheim Investigational Site

Benátky nad Jizerou, , Czechia

Site Status

1235.6.42006 Boehringer Ingelheim Investigational Site

Brno, , Czechia

Site Status

1235.6.42001 Boehringer Ingelheim Investigational Site

Pilsen, , Czechia

Site Status

1235.6.42003 Boehringer Ingelheim Investigational Site

Prague, , Czechia

Site Status

1235.6.42004 Boehringer Ingelheim Investigational Site

Příbram, , Czechia

Site Status

1235.6.42005 Boehringer Ingelheim Investigational Site

Slaný, , Czechia

Site Status

1235.6.42007 Boehringer Ingelheim Investigational Site

Strakonice, , Czechia

Site Status

1235.6.35304 Wilmer Road

Birr, , Ireland

Site Status

1235.6.35305 Dr. Ger McLaughlin

Carrigtohill, , Ireland

Site Status

1235.6.35302 Slaney Medical Centre

Enniscorthy, , Ireland

Site Status

1235.6.35303 Gorey Medical Centre, Coral House,

Gorey, , Ireland

Site Status

1235.6.35306 The Red House Surgery

Mallow, , Ireland

Site Status

1235.6.35301 Boehringer Ingelheim Investigational Site

New Ross, , Ireland

Site Status

1235.6.39002 Boehringer Ingelheim Investigational Site

Broni (pv), , Italy

Site Status

1235.6.39006 Boehringer Ingelheim Investigational Site

Coppito (AQ), , Italy

Site Status

1235.6.39001 Boehringer Ingelheim Investigational Site

Ferrara, , Italy

Site Status

1235.6.64003 Boehringer Ingelheim Investigational Site

Dunedin, , New Zealand

Site Status

1235.6.64002 Boehringer Ingelheim Investigational Site

Otahuhu, Auckland, , New Zealand

Site Status

1235.6.64001 Boehringer Ingelheim Investigational Site

Tauranga, , New Zealand

Site Status

1235.6.70004 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

1235.6.70005 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

1235.6.70006 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

1235.6.70007 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

1235.6.70008 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

1235.6.70009 Boehringer Ingelheim Investigational Site

Moscow, , Russia

Site Status

1235.6.70010 Boehringer Ingelheim Investigational Site

Saint Petersburg, , Russia

Site Status

1235.6.70011 Boehringer Ingelheim Investigational Site

Saint Petersburg, , Russia

Site Status

1235.6.70012 Boehringer Ingelheim Investigational Site

Saint Petersburg, , Russia

Site Status

1235.6.42103 Boehringer Ingelheim Investigational Site

Dolný Kubín, , Slovakia

Site Status

1235.6.42106 Boehringer Ingelheim Investigational Site

Kralovsky Chmlec, , Slovakia

Site Status

1235.6.42104 Boehringer Ingelheim Investigational Site

Liptovský Mikuláš, , Slovakia

Site Status

1235.6.42102 Boehringer Ingelheim Investigational Site

Považská Bystrica, , Slovakia

Site Status

1235.6.42105 Boehringer Ingelheim Investigational Site

Prešov, , Slovakia

Site Status

1235.6.42101 Boehringer Ingelheim Investigational Site

Trenčín, , Slovakia

Site Status

1235.6.42107 Boehringer Ingelheim Investigational Site

Vráble, , Slovakia

Site Status

1235.6.34008 Hospital Municipal de Badalona

Badalona, , Spain

Site Status

1235.6.34009 Boehringer Ingelheim Investigational Site

Barcelona, , Spain

Site Status

1235.6.34001 Hospital Gral de Jerez de la Frontera

Jerez de La Frontera (Cádiz), , Spain

Site Status

1235.6.34006 C.A.P. Mossen Cinto Verdaguer

L'Hospitalet de Llobregat (Barcelona), , Spain

Site Status

1235.6.34003 Hospital Doce de Octubre

Madrid, , Spain

Site Status

1235.6.34004 Hospital La Princesa

Madrid, , Spain

Site Status

1235.6.34011 Boehringer Ingelheim Investigational Site

Santa Coloma de Gramanet, , Spain

Site Status

1235.6.41005 Boehringer Ingelheim Investigational Site

Gordola, , Switzerland

Site Status

1235.6.90004 Boehringer Ingelheim Investigational Site

Erzurum, , Turkey (Türkiye)

Site Status

1235.6.90003 Boehringer Ingelheim Investigational Site

Istanbul, , Turkey (Türkiye)

Site Status

1235.6.90005 Boehringer Ingelheim Investigational Site

Istanbul, , Turkey (Türkiye)

Site Status

1235.6.90001 Boehringer Ingelheim Investigational Site

Izmir, , Turkey (Türkiye)

Site Status

1235.6.38010 Boehringer Ingelheim Investigational Site

Dnipro, , Ukraine

Site Status

1235.6.38001 Boehringer Ingelheim Investigational Site

Kharkiv, , Ukraine

Site Status

1235.6.38003 Boehringer Ingelheim Investigational Site

Kharkiv, , Ukraine

Site Status

1235.6.38008 Boehringer Ingelheim Investigational Site

Kharkiv, , Ukraine

Site Status

1235.6.38011 Boehringer Ingelheim Investigational Site

Kharkiv, , Ukraine

Site Status

1235.6.38004 Boehringer Ingelheim Investigational Site

Kiev, , Ukraine

Site Status

1235.6.38006 Boehringer Ingelheim Investigational Site

Kiev, , Ukraine

Site Status

1235.6.38012 Boehringer Ingelheim Investigational Site

Kiev, , Ukraine

Site Status

1235.6.38013 Boehringer Ingelheim Investigational Site

Kiev, , Ukraine

Site Status

1235.6.38002 Boehringer Ingelheim Investigational Site

Lviv, , Ukraine

Site Status

1235.6.38005 Boehringer Ingelheim Investigational Site

Odesa, , Ukraine

Site Status

1235.6.38009 Boehringer Ingelheim Investigational Site

Odesa, , Ukraine

Site Status

1235.6.38007 Boehringer Ingelheim Investigational Site

Zaporizhzhya, , Ukraine

Site Status

1235.6.44010 Boehringer Ingelheim Investigational Site

Bexhill-on-Sea, , United Kingdom

Site Status

1235.6.44008 Boehringer Ingelheim Investigational Site

Blackpool, , United Kingdom

Site Status

1235.6.44016 Boehringer Ingelheim Investigational Site

Blackpool, , United Kingdom

Site Status

1235.6.44011 Boehringer Ingelheim Investigational Site

Burbage, Hinkley, , United Kingdom

Site Status

1235.6.44007 Boehringer Ingelheim Investigational Site

Chestfield, Whitstable, , United Kingdom

Site Status

1235.6.44005 Boehringer Ingelheim Investigational Site

Chorley, , United Kingdom

Site Status

1235.6.44002 Boehringer Ingelheim Investigational Site

Edgbaston, Birmingham, , United Kingdom

Site Status

1235.6.44009 Boehringer Ingelheim Investigational Site

Ely, , United Kingdom

Site Status

1235.6.44001 Boehringer Ingelheim Investigational Site

Fowey, , United Kingdom

Site Status

1235.6.44003 Boehringer Ingelheim Investigational Site

Glasgow, , United Kingdom

Site Status

1235.6.44012 Boehringer Ingelheim Investigational Site

Penzance, , United Kingdom

Site Status

1235.6.44013 Boehringer Ingelheim Investigational Site

Plymouth, , United Kingdom

Site Status

1235.6.44004 Boehringer Ingelheim Investigational Site

Reading, , United Kingdom

Site Status

1235.6.44015 Boehringer Ingelheim Investigational Site

Saint Stephen, Saint Austell, , United Kingdom

Site Status

1235.6.44014 Boehringer Ingelheim Investigational Site

Saltash, , United Kingdom

Site Status

1235.6.44006 Boehringer Ingelheim Investigational Site

Whitstable, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia Austria Bulgaria Czechia Ireland Italy New Zealand Russia Slovakia Spain Switzerland Turkey (Türkiye) Ukraine United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EUDRACT 2007-002421-68

Identifier Type: -

Identifier Source: secondary_id

1235.6

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine
NCT01911780 COMPLETED PHASE3
Telmisartan+Amlodipine Fixed Dose Combination in Hypertension
NCT01204398 COMPLETED PHASE3
Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus
NCT00877929 COMPLETED PHASE3
Filtered Trial for Telmisartan 40mg Non-responder
NCT00550953 COMPLETED PHASE3
Telmisartan, Amlodipine and Combination in Healthy Subjects
NCT01181011 COMPLETED PHASE1
Add-on to Micamlo BP Trial
NCT01975246 COMPLETED PHASE3
Comparison in Japan T80/A5 (Telmisartan 80 mg and Amlodipine 5 mg) and T40/A5 (Telmisartan 40 mg and Amlodipine 5 mg)
NCT01286558 COMPLETED PHASE3
Telmisartan 80mg Non-responder Trial
NCT01222520 COMPLETED PHASE3
Filtered Trial for Amlodipine Non-responder
NCT00558064 COMPLETED PHASE3
Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of 40 mg Telmisartan/5 mg Amlodipine and 80 mg Telmisartan/5 mg Amlodipine in Healthy Male Volunteers
NCT02194309 COMPLETED PHASE1
Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension
NCT00281580 COMPLETED PHASE3
Telmisartan and Amlodipine Versus Monocomponent Tablets
NCT01278797 COMPLETED PHASE1
Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine
NCT00509470 COMPLETED PHASE4
Telmisartan80/HCTZ25 Versus Telmisartan80/HCTZ12.5 in Hypertension Not Responding to Telmisartan80/HCTZ12.5
NCT00239369 COMPLETED PHASE3
S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension
NCT03226340 UNKNOWN PHASE4
To Evaluate Real-world Safety, Effectiveness and Appropriate Use of Micatrio® Combination Tablets Treatment in Patients With Hypertension
NCT03021265 COMPLETED
An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination
NCT00618774 COMPLETED PHASE3
Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Essential Hypertension
NCT00940667 COMPLETED PHASE3
Relative Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers
NCT02259803 COMPLETED PHASE1
TElmisartan and AMlodipine Single Pill sTudy With Patients Not on Goal With Mono rAas Therapy-switch
NCT01134393 COMPLETED PHASE3
Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension
NCT00326768 COMPLETED PHASE3
Open-label Follow-up Trial of Fixed Dose Combination of Telmisartan + Hydrochlorothiazide in Hypertensive Patients
NCT00267943 COMPLETED PHASE3
Bioequivalence of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers
NCT02193308 COMPLETED PHASE1
Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg FDC Tablet and Telmisartan 80 mg Tab and Amlodipine 5 mg Tab Concomitant Use
NCT01344629 COMPLETED PHASE1
Parallel-Group Comparison of Olmesartan (OLM), Amlodipine (AML) and Hydrochlorothiazid (HCTZ) in Hypertension
NCT00923091 COMPLETED PHASE3